MODIFIED MRI CONTRAST AGENTS AND USES THEREOF
The present disclosure generally provides compounds useful as MRI contrast agents. In some aspects, the disclosure provides MRI contrast agents that are chemically modified to have one or more moieties that include hydrophobic portions. In some aspects, the disclosure provides compositions that include such modified MRI contrast agents and a protein, such as albumin or albumin mimetics. Further, the disclosure provides various uses of these compounds and compositions.
1 . A compound of formula (I)
A 1 -X 1 —X 2 -A 2 (I)
wherein:
A 1 is an organic group; or A 1 is a hydrophilic group or a hydrogen atom;
A 2 is an MRI contrast agent moiety;
X 1 is a hydrophobic group; and
X 2 is a direct bond, an organic group, —O—, —S—, —S(═O)—, —S(═O) 2 —, —S—S—, —N═, ═N—, —N(H)—, —N═N—N(H)—, —N(H)—N═N—, —N(OH)—, or —N(═O)—.
2 . The compound of claim 1 , wherein A 1 is a carboxylic acid group, a carboxylate anion, or a carboxylate ester.
3 . The compound of claim 2 , wherein A 1 is a carboxylic acid group.
4 . The compound of any one of claims 1 to 3 , wherein the MRI contrast agent moiety has a molecular weight of no more than 1600 Da, no more than 1500 Da, or no more than 1400 Da, or no more than 1300 Da, or no more than 1200 Da, or no more than 1100 Da, or no more than 1000 Da.
5 . The compound of any one of claims 1 to 4 , wherein the MRI contrast agent moiety is an organometallic moiety.
6 . The compound of any one of claims 1 to 5 , wherein the MRI contrast agent moiety is a gadoterate moiety, gadopentatate, or pharmaceutically acceptable salts of any of the foregoing.
7 . The compound of claim 6 , wherein the MRI contrast agent moiety is a MRI contrast agent moiety.
8 . The compound of claim 7 , wherein the MRI contrast agent moiety is a moiety of the formula:
9 . The compound of any one of claims 1 to 8 , wherein X 1 is C 12-22 hydrocarbylene, which is optionally substituted.
10 . The compound of claim 9 , wherein X 1 is C 12-22 alkylene group.
11 . The compound of claim 10 , wherein X 1 is —(CH 2 ) 12 —, —(CH 2 ) 14 —, —(CH 2 ) 16 —, —(CH 2 ) 18 —, —(CH 2 ) 20 —, or —(CH 2 ) 22 —.
12 . The compound of claim 11 , wherein X 1 is —(CH 2 ) 16 —.
13 . The compound of claim 12 , wherein X 2 is —C(═O)—.
14 . The compound of claim 1 , which is a compound of the formula:
or a pharmaceutically acceptable salt thereof.
15 . A diagnostic composition comprising:
a compound of any one of claims 1 to 14 ; and
a protein, wherein the protein is human serum albumin or a protein whose sequence is at least 50% equivalent to that of human serum albumin.
16 . The diagnostic composition of claim 15 , wherein the protein is human serum albumin.
17 . The diagnostic composition of claim 15 or 16 , further comprising a carrier.
18 . The diagnostic composition of claim 17 , wherein the carrier comprises water.
19 . The diagnostic composition of claim 18 , wherein the compound and the protein are non-covalently associated with each other with a binding constant (K b ) of at least 10 2 M −1 , or at least 10 3 M −1 , or at least 10 4 M −1 , or at least 10 5 M −1 .
20 . The diagnostic composition of any one of claims 17 to 19 , wherein the compound and the protein are solvated by the carrier.
21 . The diagnostic composition of any one of claims 17 to 20 , which contains one or more compounds of any one of claims 1 to 16 and one or more proteins, wherein at least 90% by weight, or at least 95% by weight, or at least 97% by weight, or at least 99% by weight, of the compounds in the composition are bound to proteins with a binding constant (K b ) of at least 10 2 M −1 , or at least 10 3 M −1 , or at least 10 4 M −1 , or at least 10 5 M −1 .
22 . The diagnostic composition of claim 21 , wherein at least at least 90% by weight, or at least 95% by weight, or at least 97% by weight, or at least 99% by weight, of the protein-bound particles in the composition have a radius no greater than 5 nm, or no greater than 4 nm, as measured by dynamic light scattering.
23 . The diagnostic composition of any one of claims 17 to 22 , wherein the diagnostic composition is suitable for parenteral administration to a mammal, e.g., a human.
24 . The diagnostic composition of any one of claims 17 to 22 , wherein the diagnostic composition is suitable for intravenous administration to a mammal, e.g., a human.
25 . A diagnostic composition comprising:
a compound, which comprises an MRI contrast agent moiety and a protein binding moiety;
a protein, wherein the protein is human serum albumin or a protein whose sequence is at least 50% equivalent to that of human serum albumin; and
a carrier, which comprises water;
wherein the compound and the protein are non-covalently associated with each other with a binding constant (K b ) of at least 10 2 M −1 , or at least 10 3 M −1 , or at least 10 4 M −1 , or at least 10 5 M −1 ; and
wherein the compound and the protein are solvated by the carrier.
26 . The diagnostic composition of claim 25 , wherein the compound is a compound of any one of claims 1 to 16 .
27 . The diagnostic composition of claim 25 or 26 , wherein the protein is human serum albumin.
28 . The diagnostic composition of any one of claims 25 to 27 , which contains one or more compounds of any one of claims 1 to 16 and one or more proteins, wherein at least 90% by weight, or at least 95% by weight, or at least 97% by weight, or at least 99% by weight, of the compounds in the composition are bound to proteins with a binding constant (K b ) of at least 10 2 M −1 , or at least 10 3 M −1 , or at least 10 4 M −1 , or at least 10 5 M −1 .
29 . The diagnostic composition of claim 28 , wherein at least at least 90% by weight, or at least 95% by weight, or at least 97% by weight, or at least 99% by weight, of the protein-bound particles in the composition have a radius of no greater than 5 nm, or no greater than 4 nm, as measured by dynamic light scattering.
30 . The diagnostic composition of any one of claims 25 to 29 , wherein the pharmaceutical composition is suitable for parenteral administration to a mammal, e.g., a human.
31 . The diagnostic composition of any one of claims 25 to 29 , wherein the pharmaceutical composition is suitable for intravenous administration to a mammal, e.g., a human.
32 . A method of diagnosing cancer, comprising:
administering to a subject a compound of any one of claims 1 to 14 or a composition of any one of claims 15 to 31 ; and
detecting the presence or concentration of the compound, or a metabolite thereof, in the extracellular fluid of a cancerous tumor.
33 . Use of a compound of any one of claims 1 to 14 or a composition of any one of claims 15 to 31 as a diagnostic agent.
34 . Use of a compound of any one of claims 1 to 14 or a composition of any one of claims 15 to 31 for diagnosing cancer.
35 . Use of a compound of any one of claims 1 to 14 in the manufacture of a medicament.
36 . Use of a compound of any one of claims 1 to 14 in the manufacture of a medicament for diagnosing cancer.
37 . A method of imaging tissue of a subject, comprising:
administering to a subject a compound of any one of claims 1 to 14 or a composition of any one of claims 15 to 31 ; and
detecting the presence or concentration of the compound, or a metabolite thereof, in the extracellular fluid of one or more tissues of the subject.
38 . A method of imaging the vasculature of a subject, comprising:
administering to a subject a compound of any one of claims 1 to 14 or a composition of any one of claims 15 to 31 ; and
detecting the presence or concentration of the compound, or a metabolite thereof, in the vasculature of the subject.
39 . A method of imaging the liver tissue of a subject, comprising:
administering to a subject a compound of any one of claims 1 to 14 or a composition of any one of claims 15 to 31 ; and
detecting the presence or concentration of the compound, or a metabolite thereof, in the extracellular fluid of liver tissue of a subject.